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Alzheimer’s  disease  is  characterized  by  brain  plaques  of  amyloid  beta  and  by  neuronal  loss,  but  it  is  
unclear  how  amyloid  beta  causes  neuronal  loss  and  how  to  prevent  this  loss.  We  have  previously  
shown  that  amyloid  beta  causes  neuronal  loss  by  inducing  microglia  to  phagocytose  neurons,  and  
here  we  investigated  whether  protein  kinase  Cs  and  NADPH  oxidase  were  involved  in  this.  The  loss  
of  neurons  induced  by  amyloid  beta  in  co-­cultures  of  primary  glia  and  neurons  was  completely  
prevented  by  inhibiting  protein  kinase  Cs  with  Gö6976  or  Gö6983.  Directly  activating  protein  kinase  
Cs  with  phorbol  myristate  acetate  stimulated  microglial  phagocytosis,  and  induced  neuronal  loss  
mediated  by  MFG-­E8/vitronectin  receptor  pathway  of  microglial  phagocytosis.  Blocking  phagocytosis  
by  MFG-­E8  knockout  or  receptor  inhibition  left  live  neurons,  indicating  microglial  phagocytosis  was  
the  cause  of  neuronal  death.  Phorbol  myristate  acetate  stimulated  the  microglial  NADPH  oxidase,  and  
inhibiting  the  oxidase  prevented  neuronal  loss.  A  physiological  activator  of  NADPH  oxidase,  fMLP,  
also  induced  neuronal  loss  dependent  on  microglia.  Amyloid  beta-­induced  neuronal  loss  was  blocked  
by  NADPH  oxidase  inhibitors,  superoxide  dismutase  or  Toll-­like  receptor  function-­blocking  antibodies.  
	   2	  
The  results  indicate  that  amyloid  beta  induces  microglial  phagocytosis  of  neurons  via  activating  
protein  kinase  Cs  and  NADPH  oxidase,  and  that  activating  the  kinases  or  oxidase  is  sufficient  to  
induce  neuronal  loss  by  microglial  phagocytosis.  Thus  inhibiting  protein  kinase  Cs  or  NADPH  oxidase  
might  be  beneficial  in  Alzheimer’s  disease  or  other  brain  pathologies  involving  inflammatory  neuronal  
loss  mediated  by  microglia.  
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1.  Introduction  
Brain  damage,  infection  and  neurodegeneration  result  in  brain  inflammation,  often  accompanied  by  
loss  of  neurons  and/or  synapses  (Glass  et  al.,  2010,  Heneka  et  al.,  2014,  Heneka  et  al.,  2015).  
Behind  an  intact  blood-­brain  barrier,  neuroinflammation  is  mediated  by  microglia,  the  brain’s  main,  
resident  macrophages  (Ransohoff  and  Perry,  2009,  Gomez-­Nicola  and  Perry,  2015).  In  the  healthy  
brain,  microglia  are  ‘resting’,  but  if  microglia  detect  damage,  infection  or  protein  aggregates  they  
become  ‘activated’.  Microglial  activation  is  mediated  by  pattern  recognition  receptors  such  as  the  Toll-­
like  receptors  (TLRs),  which  activate  transcription  factors  such  as  NF-­κB  (nuclear  factor  kappa-­light-­
chain-­enhancer  of  activated  B  cells),  which  cause  expression  of  pro-­inflammatory  cytokines.  The  
activated  microglia  become  amoeboid,  motile  and  highly  phagocytic  (Ransohoff  and  Perry,  2009,  
Gomez-­Nicola  and  Perry,  2015),  and  may  protect  neurons  by  killing  pathogens,  removing  debris  and  
aiding  repair,  but  they  may  also  damage  or  kill  neurons  (Brown  and  Neher,  2010).  Understanding  how  
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microglia  damage  neurons  and  how  this  is  regulated  is  important  to  understanding  how  to  prevent  
neuronal  damage  in  brain  pathology.  
We  have  found  that  inflammatory  activation  of  microglia  can  cause  delayed  neuronal  loss  in  
culture  and  in  vivo  via  activating  microglial  phagocytosis  of  stressed-­but-­viable  neurons  (Neher  et  al.,  
2011).  Cell  death  by  phagocytosis  (called  ‘phagoptosis’  for  short)  has  the  defining  characteristic  that  
inhibition  of  phagocytosis  or  phagocytic  signalling  prevents  death  of  the  cell  (Brown  and  Neher,  2012).  
Inflammatory  stimuli  found  to  activate  microglial  phagocytosis  of  neurons  include  lipopolysaccharide  
(LPS)  and  lipoteichoic  acid  that  activate  microglia  via  TLR4  or  TLR2  respectively  (Neher  et  al.,  2011),  
tumour  necrosis  factor  α  (TNFα)  that  activates  via  TNF  receptors  (Neniskyte  et  al.,  2014)  and  
rotenone  that  activates  via  inhibition  of  mitochondrial  complex  I  (Emmrich  et  al.,  2013).  Activation  of  
microglia  causes:  i)  increased  phagocytic  capacity  of  microglia,  ii)  release  of  oxidants  from  microglia  
that  induce  neurons  to  reversibly  expose  the  ‘eat-­me’  signal  phosphatidylserine,  and  iii)  release  of  the  
opsonin  milk  fat  globule  EGF  factor-­8  (MFG-­E8)  from  microglia  and  astrocytes  that  binds  exposed  
phosphatidylserine  on  neurons  and  promotes  their  phagocytosis  by  also  binding  and  activating  the  
microglial  vitronectin  receptor  (VNR)  (Neher  et  al.,  2011,  Neher  et  al.,  2013,  Brown  and  Neher,  2014).  
Alzheimer’s  disease  is  characterised  by  tau  tangles  and  amyloid  plaques,  the  latter  consisting  mainly  
of  aggregated  peptide  amyloid  beta  (Aβ).  High  concentrations  of  Aβ  can  kill  neurons  directly,  but  
lower  concentrations  kill  neurons  indirectly  by  activating  microglia  (Neniskyte  et  al.,  2011).  We  have  
shown  that  Aβ  can  induce  a  delayed  loss  of  neurons  and  synapses  mediated  by  neuronal  exposure  of  
phosphatidylserine,  binding  the  opsonin  MFG-­E8  that  then  drives  phagocytosis  of  the  neurons  via  the  
vitronectin  receptor  (Neniskyte  et  al.,  Neniskyte  and  Brown).  However,  we  do  not  know  what  regulates  
this  process,  and  therefore  how  it  might  be  prevented.  
Aβ  binds  to  TLR-­2  and  TLR-­4  and  activates  the  phagocyte  NADPH  oxidase  (PHOX)  in  
microglial  cells  (Reed-­Geaghan  et  al.,  2009),  which  in  turn  upregulates  production  of  pro-­inflammatory  
cytokines,  such  as  tumour  necrosis  factor-­α,  and  expression  of  inducible  nitric  oxide  synthase  (Combs  
et  al.,  2001,  Jekabsone  et  al.,  2006).  Microglia  highly  express  PHOX,  which  when  activated  produces  
superoxide  that  can  either  dismutate  to  hydrogen  peroxide,  or  react  with  NO  to  produce  peroxynitrite  
(Bal-­Price  et  al.,  2002).  Superoxide  and  NO  synergise  to  induce  neuronal  death  (Mander  and  Brown,  
2005)  and  their  reaction  product  peroxynitrite  can  stress  neurons  to  expose  phosphatidylserine  and  
thereby  induce  phagoptosis  (Neher  et  al.,  2011).  
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PHOX  is  regulated  by  protein  kinases  C  (PKCs),  which  phosphorylate  the  cytosolic  
components  of  PHOX  to  cause  assembly  on  the  membrane  (Gao  et  al.,  2012).  Classical  PKCs  (α,  β  
or  γ)  are  implicated  in  Aβ-­induced  activation  of  microglia  (Combs  et  al.,  1999).  We  recently  found  that  
inflammatory  stimuli  induce  multinucleation  of  microglia  via  PKCs,  and  that  PKC  activator  phorbol  12-­
myristate  13-­acetate  (PMA)  induces  microglia  to  form  giant  multinucleated  cells  that  are  highly  
phagocytic  (Hornik  et  al.,  2014).  
Therefore,  in  the  presented  work,  we  investigated  whether  NADPH  oxidase  or  PKC  activation  
are  necessary  for  the  microglial  phagocytosis  of  neurons  induced  by  Aβ,  and  whether  activation  of  





Aβ1-­42  peptide  (EZBiolab),  Alexa  Fluor  488  conjugate  of  isolectin  B4  from  Griffonia  simplicifolia  
(Invitrogen),  carboxylate-­modified  fluorescent  microspheres  (Invitrogen),  cyclo(RGDfV)  and  
cyclo(RADfV)  peptides  (Bachem),  apocynin,  Gö6976  and  Gö6983  (Calbiochem),  TNFα  Quantikine  
Elisa  Kit  (R&D  Systems),  function  blocking  antibodies  to  TLR4  (HTA-­125),  TLR2  (T2.5)  and  isotype  
control  antibodies  IgG1,  IgG2a  (eBioscience).  Cell  culture  reagents  were  from  PAA.  Other  reagents  
were  from  Sigma.  
Monomeric  amyloid  β  peptide  1–42  was  prepared  as  described  previously  (Demuro  et  al.,  
2005,  Cizas  et  al.,  2010):  1.0  mg  of  lyophilised  peptide  was  dissolved  in  400  μL  1,1,1,3,3,3-­
hexafluorisopropanol  and  solution  was  incubated  for  30–60  minutes  at  room  temperature  to  ensure  
complete  removal  of  any  pre-­existing  secondary  structure.  To  prepare  monomeric  Aβ1-­42  HFIP  was  
removed  by  evaporation  and  the  peptide  was  resuspended  in  DMSO  at  a  concentration  of  5  mM.      
  
2.2  Primary  cell  culture  and  treatment  
All  experiments  were  performed  in  accordance  with  the  UK  Animals  (Scientific  Procedures)  Act  (1986)  
and  approved  by  the  Cambridge  University  local  ethical  committee.  Mixed  neuronal/glial  cultures  were  
prepared  from  the  cerebella  of  postnatal  day  5-­7  rats  or  mice  as  previously  described  (Kinsner  et  al.,  
2005).  Mixed  neuronal/glial  cells  were  plated  at  a  density  of  5×105  cells/well  on  poly-­l-­lysine  coated  
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24-­well  plates  in  DMEM  supplemented  with  5  %  foetal  calf  serum,  5  %  horse  serum,  20  mM  KCl,  13  
mM  D-­glucose,  5  mM  HEPES,  2  mM  L-­glutamine  and  antibiotics  penicillin/streptomycin  (100  U/ml  and  
100  μg/ml  respectively).  The  cultures  were  allowed  to  mature  in  vitro  for  at  least  7  days  prior  to  
treatment,  when  they  contained  85±5%  neurons,  7±3%  astrocytes,  and  5±3%  microglia.  Some  
cultures  were  prepared  from  Mfge8-­/-­  mice  from  Clotilde  Théry  (Silvestre  et  al.)  and  Bax-­/-­  mice  
(originally  from  Stanley  Korsmeyer,  crossed  into  a  CD1  background  by  Aviva  Tolkovsky  (Wyttenbach  
and  Tolkovsky)).  Microglia  were  selectively  eliminated  from  cultures  (where  indicated)  by  addition  of  
L-­leucine  methyl  ester  (LME,  Sigma)  as  previously  described  (Neher  et  al.,  2011).  
The  cultures  were  allowed  to  mature  for  7–9  days  in  vitro  and  were  then  stimulated  for  three  
days  with  Aβ  (250  nM),  phorbol  12-­myristate  13-­acetate  (PMA,  30  nM),  or  formyl-­L-­methionyl-­L-­
leucyl-­L-­phenylalanine  (fMLP,  10  –  100  μM),  with  or  without  cyclo(RGDfV)  peptide  (50  μM),  
superoxide  dismutase  (SOD,  100  U/ml),  4-­(2-­aminoethyl)benzenesulfonyl  fluoride  hydrochloride  
(AEBSF,  20  μM),  apocynin  (100  μM),  Gö6976  (0.1  –  1  μM)  or  Gö6983  (0.1  –  1  μM)  in  regular  cell  
culture  medium.  Cell  densities  and  cell  death  three  days  after  treatment  were  evaluated  as  described  
previously  (Neniskyte  et  al.,  2011).  Neurons  with  regular  soma  shape  and  normal  nuclear  Hoechst  
33342  staining  (10  µg/ml)  were  counted  as  alive,  neurons  with  condensed  chromatin  were  considered  
as  apoptotic,  whereas  neurons  staining  with  propidium  iodide  staining  (1  µg/ml)  were  defined  as  
necrotic.  For  some  treatments,  TNFα  was  measured  in  culture  media  at  3  days  after  stimulation  using  
Quantikine  Elisa  Kit  (R&D  Systems)  following  manufacturer’s  instructions.  
  
2.3  Phagocytosis  assay  
Phagocytic  capacity  of  microglial  cells  was  evaluated  as  described  previously  (Neniskyte  et  al.,  2011).  
In  short,  pure  microglial  culture  was  treated  with  30  nM  PMA  for  24  hours  before  3  μl  of  1:10  dilution  
of  1  μm  fluorescently  labelled  carboxylate-­modified  microspheres  were  added,  and  cells  were  
incubated  for  1  hour  at  37  °C,  5%  CO2.  The  medium  was  removed,  and  the  culture  was  washed  
several  times  to  remove  excess  beads.  Microglia  cells  were  then  labelled  with  Alexa  Fluor  488-­tagged  
isolectin  B4  (2  μg/ml)  and  bead  number  per  cell  was  evaluated  in  >50  cells  per  condition.  
  
2.4  Nitro-­blue  tetrazolium  (NBT)  assay  to  measure  superoxide  production  
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After  stimulation,  mixed  neuronal/glial  cultures  were  incubated  with  1  mg/ml  of  NBT  for  30  min  at  
37  °C.  Then  cells  were  washed  to  remove  remaining  NBT  and  cells  containing  dark  formazan  
precipitate  were  identified  under  a  transmission  light  microscope.  
  
2.5  Measurement  of  H2O2  production  by  microglial  cells  
H2O2  production  by  microglia  was  measured  in  a  fluorometric  Amplex  Red  hydrogen  
peroxide/peroxidase  assay.  Isolated  microglia  were  suspended  in  HBSS  supplemented  with  50  mM  
D-­glucose.  The  reaction  mixture  of  a  control  sample  contained  6×104  microglia  cells  in  black  96-­well  
plate,  15  μM  Amplex  Red  and  30  μg/ml  horseradish  peroxidase.  Production  of  reactive  oxygen  
species  in  microglial  cells  was  induced  by  the  treatment  with  PMA  (30  nM).  PKC  inhibitors  Gö6976  
(1  μM)  and  Gö6983  (1  μM)  were  added  together  with  the  stimulant.  The  rate  of  H2O2  production  was  
assessed  for  two  hours  by  continuously  measuring  fluorescence  development  in  a  Fluorstar  Optima  
plate  reader  (BMG  Labtechnologies)  with  excitation  at  550  ±  10  nm  and  emission  at  590  ±  10  nm.  
  
2.6  Assessment  of  NO  levels  in  cell  culture  medium  
Nitric  oxide  production  was  evaluated  by  the  accumulation  of  nitrite,  which  is  a  stable  break  down  
product  of  NO.  Levels  of  nitrite  were  assessed  using  the  Griess  reaction,  which  quantifies  nitrite  
through  the  formation  of  a  red  azo  dye.  Cell  culture  supernatants  (50  μl)  were  added  to  a  96-­well  plate  
and  mixed  with  50  μl  of  ice-­cold  sulfanilamide  (2  mM)  in  hydrochloric  acid  (1.2  M).  The  mixture  was  
incubated  for  10  minutes  at  room  temperature,  protected  from  light.  Then  N-­1-­(1-­
naphtyl)ethylenediamine  (3  mM,  50  μl)  was  added  followed  by  another  incubation  for  10  minutes  at  
room  temperature,  protected  from  light.  The  absorbance  of  the  resulting  reaction  solution  was  
measured  at  550  ±  10  nm  wavelength  in  a  Fluorstar  Optima  plate  reader  (BMG  Labtechnologies)  with  
wavelength  correction  at  380  ±  10  nm.  
  
2.7  Statistical  analysis  
For  all  experiments,  each  treatment  condition  was  repeated  at  least  in  duplicate  for  each  culture,  and  
then  repeated  in  at  least  three  independent  cultures,  for  statistical  analysis  means  of  each  
independent  culture  were  used  as  repeats  (n).  Statistical  analysis  was  performed  using  IBM  SPSS  
Statistics  v20  software.  Normality  of  data  was  verified  by  Shapiro-­Wilk  test.  Means  were  compared  by  
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one-­way  ANOVA  and  post-­hoc  Bonferroni  test.  p  values  <  0.05  were  considered  as  significant.  
Numbers  of  alive,  apoptotic  and  necrotic  neurons  were  compared  separately.  All  data  presented  are  




3.1  Active  PKC  is  necessary  and  sufficient  for  Aβ-­induced  neuronal  loss  
We  have  previously  shown  that  nanomolar  levels  of  Aβ  can  induce  delayed  neuronal  loss  in  mixed  
neuronal-­glial  culture  mediated  by  microglial  phagocytosis  of  stressed-­but-­viable  neurons  (Neniskyte  
et  al.,  2011).  Cultures  were  treated  with  250  nM  monomeric  Aβ  for  three  days,  resulting  in  loss  of  
about  30%  of  the  neurons  without  any  increase  in  neuronal  apoptosis  or  necrosis  (Fig.  1).  These  
conditions  were  chosen  as  we  had  previously  found  that:  monomeric,  oligomeric  and  fibrillar  Aβ  
caused  similar  neuronal  loss  (different  forms  are  likely  to  equilibrate  over  3  days),  10-­250  nM  Aβ  
caused  similar  neuronal  loss  but  loss  was  more  reproducible  at  250  nM,  and  the  neuronal  loss  was  
delayed  until  1-­2  days  after  Aβ  addition  (Neniskyte  et  al.,  Neniskyte  and  Brown).  
We  tested  here  whether  this  neuronal  loss  could  be  prevented  by  PKC  inhibitors  Gö6976  (an  
inhibitor  of  PKCα,  PKCβI  and  PKCμ  (Martiny-­Baron  et  al.)  as  well  as  Trk  A  an  Trk  B)  or  Gö6983  (an  
inhibitor  of  PKCα,  PKCβ,  PKCγ,  PKCδ  and  PKCζ  (Gschwendt  et  al.)).  Both  inhibitors  completely  
prevented  Aβ-­induced  neuronal  loss,  leaving  live  neurons  (Fig.  1),  indicating  that  one  or  more  PKCs  
(possibly  PKCα  or  PKCβ,  based  on  the  overlap  of  the  specificity  of  the  two  inhibitors  used)  mediate  
Aβ-­induced  neuronal  loss  and  death.  
As  PKC  activity  was  necessary  for  Aβ-­induced  neuronal  loss,  we  tested  whether  activating  
PKCs  with  PMA  was  sufficient  to  induce  neuronal  loss,  and  if  so  by  what  means.  We  found  that  30  nM  
PMA  induced  a  similar  amount  of  neuronal  loss  as  Aβ  over  three  days  in  culture,  without  significantly  
increasing  the  level  of  neuronal  apoptosis  or  necrosis  (Fig.  2A,B).  The  PMA-­induced  neuronal  loss  
was  completely  prevented  by  pre-­treating  the  cultures  with  L-­leucine  methyl  ester  (LME)  to  eliminate  
microglia,  leaving  live  neurons  (Fig.  2B),  indicating  that  PMA  was  not  directly  toxic  to  neurons  and  the  
neuronal  loss/death  was  mediated  by  microglia.  
PMA  can  activate  a  variety  of  PKCs,  but  also  other  kinases  such  as  protein  kinase  D  (PKD),  
so  we  tested  whether  the  PMA-­induced  neuronal  loss  could  be  blocked  by  the  PKC  inhibitors  Gö6976  
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and  Gö6983.  We  found  that  PMA-­induced  neuronal  loss  could  be  completely  blocked  by  either  
Gö6976  or  Gö6983  (Fig.  2C,D),  indicating  that  PMA-­induces  neuronal  loss  by  activating  PKCs  
(possibly  PKCα  or  PKCβ).  
To  further  test  whether  apoptosis  was  involved  in  the  neuronal  loss,  mixed  neuronal-­glial  
cultures  were  prepared  from  Bax  knockout  mice.  Due  to  availability  we  used  Bax  knockout  mice  
rather  than  rats.  Post-­mitotic  neurons  are  wholly  reliant  on  the  expression  of  BAX  for  induction  of  
apoptosis  via  the  mitochondrial  pathway,  as  they  do  not  express  full  length  Bak  (Deckwerth  et  al.,  Sun  
et  al.).  However,  PMA-­induced  neuronal  loss  was  the  same  in  these  cultures  as  in  wild-­type  cultures  
(Fig.  3),  indicating  that  PMA-­induced  neuronal  loss  did  not  involve  mitochondrial  apoptosis.  
Inflammatory  activation  of  microglia  can  cause  TNFα  expression  and  release,  and  we  have  
shown  that  high,  sustained  levels  of  TNFα  (100  ng/ml)  can  cause  neuronal  loss  mediated  by  
microglial  phagocytosis  (Neniskyte  et  al.).  However,  we  found  that  PMA  caused  little  or  no  TNFα  
release  in  the  cultures.  TNFα  levels  detected  by  ELISA  in  medium  of  glial-­neuronal  cultures  3  days  
after  treatment  were,  untreated:  0.2  ±  0.3  pg/ml,  PMA:  1.8  ±  0.2  pg/ml  (c.f.  positive  control  LPS  gave  
570  ±  32  pg/ml).  This  makes  it  unlikely  that  the  PMA-­induced  neuronal  loss  was  mediated  by  TNFα.  
Furthermore  this  also  indicated  that  PMA  was  not  causing  a  classical  activation  of  microglia.  
  
3.2  Microglial  phagocytosis  via  MFG-­E8  and  the  vitronectin  receptor  mediates  neuronal  loss  
As  we  had  previously  found  that  neuronal  loss  induced  by  Aβ  and  other  inflammatory  stimuli  is  
mediated  by  microglial  phagocytosis  (Neher  et  al.,  Neniskyte  et  al.),  we  tested  whether  PMA  
increased  microglial  phagocytosis.  PMA  stimulated  microglial  phagocytosis  of  negatively-­charged  
beads  (Fig.  4A),  indicating  that  PMA  increases  the  phagocytic  capacity  of  microglia.  Microglial  
phagocytic  activity  was  diminished  by  pre-­treatment  with  PKC  inhibitors  Gö6976  or  Gö6983  and  
PHOX  inhibitor  apocynin  (Fig.  4A),  indicating  that  PKC  and  subsequent  PHOX  activation  is  required  
for  microglial  phagocytosis.  
We  had  previously  found  that  neuronal  loss  induced  by  Aβ  and  other  inflammatory  stimuli  is  
mediated  by  the  phosphatidylserine/MFG-­E8/vitronectin  receptor  pathway  of  phagocytosis  [7,  19],  so  
we  tested  whether  MFG-­E8  was  required  for  PMA-­induced  neuronal  loss.  Due  to  availability  Mfge8  
knockout  mice  rather  than  rats  were  used  to  evaluate  the  role  of  MFG-­E8.  We  compared  PMA-­
induced  neuronal  loss  in  cultures  from  Mfge8  knockout  and  wild-­type  mice.  We  found  that  cultures  
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from  Mfge8  knockout  mice  completely  lacked  PMA-­induced  neuronal  loss  or  death  (Fig.  3),  indicating  
that  such  loss  and  death  requires  MFG-­E8.  This  also  indicates  that  PMA  does  not  directly  kill  
neurons,  and  that  the  neuronal  death  is  caused  by  phagocytosis.  
MFG-­E8  activates  phagocytosis  by  binding  phosphatidylserine  on  target  cells  and  the  
vitronectin  receptor  on  phagocytes.  In  order  to  test  whether  the  vitronectin  receptor  is  involved  in  
PMA-­induced  neuronal  loss,  we  inhibited  the  vitronectin  receptor  with  a  specific  inhibitor,  cRGDfV  
(50  μM).  This  completely  prevented  neuronal  loss,  without  increasing  neuronal  death  (Fig.  4B),  again  
indicating  microglial  phagocytosis  was  the  cause  of  neuronal  death  induced  by  PMA.  The  structurally  
similar  cyclic  peptide  cRADfV,  which  does  not  block  VNR  did  not  prevent  neuronal  loss  (Fig.  4B),  
indicating  the  neuroprotective  effect  of  cRGDfV  is  due  to  VNR  blocking.  
  
3.3  PHOX,  superoxide  and  TLRs  mediate  neuronal  loss  
We  had  previously  found  that  LPS-­induced  neuronal  loss  is  mediated  by  activation  of  the  PHOX  
(Neher  et  al.),  and  as  PMA  is  known  to  activate  PHOX  via  PKCs,  we  tested  here  whether  PMA  
activated  microglial  oxidant  production  via  PKCs.  We  found  that  PMA  acutely  activated  H2O2  
production  by  microglia,  and  this  was  inhibited  by  PKC  inhibitors  Gö6976  or  Gö6983  (1  µM,  Fig.  5C).  
To  test  whether  PMA  and  Aβ  induce  oxidant  production  in  the  neuronal-­glial  cultures,  we  added  PMA  
or  Aβ  to  such  cultures  and  3  days  later  assayed  oxidant  production  by  nitro  blue  tetrazolium  staining.  
This  staining  was  primarily  restricted  to  microglia  (Fig.  5A),  and  PMA  and  Aβ  increased  the  number  of  
microglia  producing  oxidants  (Fig.  5B).  In  order  to  test  whether  Aβ-­  or  PMA-­induced  neuronal  loss  
was  mediated  by  PHOX  activity,  we  added  two  different  inhibitors  of  PHOX  activation:  apocynin  (Stolk  
et  al.)  and  AEBSF  (Diatchuk  et  al.).  Apocynin  prevents  the  assembly  of  NADPH  oxidase  subunits  –  
cytoplasmic  p47phox  and  plasmalemmal  gp91phox  –  thus  arresting  its  activation  (Stolk  et  al.),  while  
AEBSF  is  a  serine  protease  inhibitor,  which  abrogates  ROS  production  by  NADPH  oxidase  by  
interfering  with  the  binding  of  its  subunits  p47phox  and/or  p67phox  to  cytochrome  b558  (gp91phox)  
(Diatchuk  et  al.).  We  found  that  inhibition  of  PHOX  by  either  100  μM  apocynin  or  20  μM  AEBSF  
prevented  neuronal  loss  induced  by  PMA  or  Aβ  (Fig.  6),  indicating  that  PHOX  activity  is  required  for  
Aβ-­  and  PMA-­induced  neuronal  loss,  and  that  both  apocynin  and  AEBSF  are  neuroprotective  in  
inflammatory  conditions.  
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PHOX  generates  extracellular  superoxide  that  either  dismutates  to  hydrogen  peroxide  (which  
promotes  microglial  activation  (Mander  et  al.))  or  reacts  with  NO  to  produce  peroxynitrite  (which  
promotes  phagoptosis  (Neher  et  al.)).  In  order  to  test  whether  superoxide  mediates  Aβ-­induced  
neuronal  loss,  we  added  to  the  cultures  superoxide  dismutase  (SOD1),  which  rapidly  dismutates  
extracellular  superoxide  to  hydrogen  peroxide.  We  found  that  addition  of  SOD1  prevented  Aβ-­induced  
neuronal  loss  (Fig.  5D),  indicating  that  extracellular  superoxide  mediates  Aβ-­induced  neuronal  loss.  
As  superoxide  can  react  with  NO  to  produce  peroxynitrite  that  promotes  phagoptosis,  we  tested  
whether  NO  was  produced  in  the  conditions  used,  and  found  that  treatment  with  Aβ  stimulated  nitric  
oxide  production  (4.8  ±  0.4  µM  compared  to  control  levels  of  1.2  ±  0.6  µM).  
Aβ  has  been  reported  to  activate  microglia  via  a  variety  of  different  receptors,  including  TLR2  
and  TLR4  (Reed-­Geaghan  et  al.).  Thus  we  tested  whether  blocking  TLR2  or  TLR4  with  function-­
blocking  antibodies  could  prevent  Aβ-­induced  neuronal  loss.  We  found  that  function-­blocking  
antibodies  to  TLR2  and  TLR4  (as  previously  published  (Reed-­Geaghan  et  al.,  2009))  each  partially  
blocked  Aβ-­induced  neuronal  loss  (Fig.  7A,B).  Combining  the  antibodies  gave  neuronal  survival  not  
significantly  different  from  the  untreated  control  (Fig.  7C).  Thus  the  data  are  consistent  with  Aβ  
inducing  neuronal  loss  via  activating  TLR2  and/or  TLR4,  which  are  known  to  activate  PKCs  and/or  
PHOX  in  microglia  (Nakajima  et  al.,  Reed-­Geaghan  et  al.,  Wen  et  al.).  
   Although  PMA  and  Aβ  activate  PHOX,  they  are  not  present  physiologically,  so  we  were  
interested  in  whether  a  physiological  activator  of  PHOX,  N-­formylmethionyl-­leucyl-­phenylalanine  
(fMLP),  could  cause  neuronal  loss  mediated  by  microglia.  We  found  that  activation  of  PHOX  with  
10  μM  fMLP  caused  neuronal  loss  without  neuronal  apoptosis  or  necrosis,  and  this  neuronal  loss  was  
prevented  by  eliminating  microglia  with  LME  (Fig  8).  Thus  physiological  activation  of  PHOX  appears  
sufficient  to  induce  microglia-­mediated  neuronal  loss.  
  
4.  Discussion  
Aβ  is  known  to  activate  PKCs  in  microglia,  and  we  have  shown  here  that  inhibition  of  PKCs  with  
Gö6976  or  Gö6983  completely  prevents  Aβ-­induced  neuronal  loss.  At  the  concentrations  used  here,  
Gö6976  is  reported  to  inhibit  PKCα,  β  and  µ  (Martiny-­Baron  et  al.  1993),  whereas  Gö6983  is  reported  
to  inhibit  PKCα,  β,  γ  and  δ  (Gschwendt  et  al.  1996).  Thus  if  one  isoform  of  PKC  is  required  for  
inflammatory  neuronal  loss  it  is  likely  to  be  PKCα  or  β.  However,  more  than  one  isoform  of  PKC  might  
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be  involved.  As  PKC  was  required  for  Aβ-­induced  neuronal  loss,  we  tested  whether  PKC  activation  
was  sufficient  to  induce  neuronal  loss  by  adding  PMA,  which  is  known  to  directly  activate  classical  
and  novel  forms  of  PKC.  We  found  that  PMA  did  induce  a  similar  level  of  neuronal  loss  to  Aβ,  and  this  
was  blocked  by  Gö6976  or  Gö6983,  indicating  that  the  neuronal  loss  was  mediated  by  classical  
PKCs.  The  PMA-­induced  neuronal  loss  was  completely  prevented  by  prior  elimination  of  microglia,  
indicating  that  PMA  was  not  directly  toxic  to  neurons,  but  rather  that  the  neuronal  loss  required  
microglia.  PMA  did  not  increase  the  number  of  apoptotic  or  necrotic  neurons  in  the  mixed  cultures,  
and  using  cultures  from  Bax  knockout  mice,  where  neurons  lack  mitochondrial  apoptosis,  had  no  
effect  on  the  neuronal  loss.  
   PMA-­induced  neuronal  loss  was  completely  prevented  in  cultures  from  Mfge8  knockout  mice,  
indicating  that  MFG-­E8-­mediated  phagocytosis  was  required  for  neuronal  loss.  PMA  increased  the  
phagocytic  capacity  of  microglia,  and  blocking  the  vitronectin  receptor  (VNR)  required  for  MFG-­E8-­
mediated  phagocytosis,  prevented  PMA-­induced  neuronal  loss.  The  neurons  saved  from  
phagocytosis  by  blocking  MFG-­E8  or  VNR  were  viable.  If  the  microglia  had  killed  neurons  first  before  
phagocytosing  them,  then  inhibition  of  phagocytosis  would  have  left  dead  neurons.  Thus  PMA-­
induced  neuronal  death  was  caused  by  phagocytosis  of  the  neurons  by  microglia  –  a  form  of  neuronal  
death  that  we  and  other  have  found  in  a  variety  of  inflammatory  conditions  in  culture  and  in  vivo  
(reviewed  in  (Brown  and  Neher).  
   How  does  PKC  activation  lead  to  neuronal  loss?  There  are  probably  a  variety  of  processes  
involved,  but  we  find  that  PMA  activates  the  NADPH  oxidase  in  a  PKC-­dependent  manner,  and  
inhibiting  the  NADPH  oxidase  with  AEBSF  or  apocynin  prevents  PMA-­  or  Aβ-­induced  neuronal  loss.  A  
physiological  activator  of  the  NADPH  oxidase  fMLP  also  induced  neuronal  loss  via  microglia.  Thus  
PMA/PKC  may  induce  neuronal  loss  via  activation  of  NADPH  oxidase.  The  NADPH  oxidase  produces  
superoxide,  which  may  either  dismutate  to  hydrogen  peroxide,  which  promotes  activation  of  microglia  
(Mander  et  al.,  Jekabsone  et  al.),  or  may  react  with  NO  to  give  peroxynitrite  (Bal-­Price  et  al.),  which  
can  stress  neurons  to  expose  phosphatidylserine  that  promotes  their  phagocytosis  by  microglia  
(Neher  et  al.).  We  found  that  addition  of  superoxide  dismutase  to  the  culture  medium  prevented  Aβ-­
induced  neuronal  loss.  This  suggests  that  the  neuronal  loss  is  mediated  by  extracellular  superoxide  
reacting  with  NO  to  produce  peroxynitrite  that  stresses  neurons.  
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The  NADPH  oxidase  has  previously  been  implicated  in  AD  and  other  neurodegenerative  
pathologies  (Sorce  and  Krause,  2009,  Block,  2008).  The  findings  reported  here  support  this  idea,  but  
also  suggest  a  novel  mechanism  by  which  this  occurs  i.e.  by  driving  microglial  phagocytosis  of  
stressed-­but-­viable  neurons.  
   Aβ-­induced  neuronal  loss  was  at  least  partially  prevented  by  blocking  TLR2  and  TLR4,  
indicating  that  TLR2/4  may  mediate  the  activation  of  microglia  by  Aβ.  And  this  may  explain  why  the  
neuronal  loss  induced  Aβ,  LPS  (a  TLR4  agonist)  and  lipoteichoic  acid  (a  TLR2  agonist)  are  similar.  
Alternatively,  they  may  be  similar  because  they  all  activate  PKCs  to  drive  neuronal  loss.  
   Alzheimer’s  disease  is  characterised  by  tau  tangles  and  amyloid  plaques  (containing  Aβ).  The  
disease  is  also  accompanied  by  neuroinflammation  and  extensive  loss  of  neurons  and  synapses,  
which  probably  cause  the  dementia.  However,  there  is  little  or  no  evidence  of  excess  neuronal  death  
in  AD  patient  brains  compared  with  age-­matched  controls  (Perry  et  al.,  1998,  Raina  et  al.,  2000,  
Calissano  et  al.,  2009).  One  possible  explanation  for  this  is  that  neuronal  death  rates  are  low,  and  the  
dead  neurons  are  removed  almost  immediately  after  they  die  (Perry  et  al.,  1998).  An  alternative  
explanation  is  that  the  neurons  are  removed  by  phagocytosis  before  they  die,  and  this  explanation  is  
supported  by  the  results  reported  here,  at  least  for  Aβ-­induced  neuronal  loss  in  vitro.  
Others  have  shown  that  phagocytosis  of  otherwise-­viable  neurons  by  activated  microglia  
mediates  neuronal  loss  and  death  in  models  of  AIDS  dementia  (Marker  et  al.,  2012),  Parkinson’s  
disease  (Barcia  et  al.,  2012,  Bodea  et  al.,  2014)  and  Motor  Neuron  Disease  (Liu  et  al.,  2012),  as  well  
as  developmental  loss  of  neuronal  precursors  that  may  be  related  to  autism  spectrum  disorders  or  
schizophrenia  (Cunningham  et  al.,  2013)  and  loss  of  photoreceptor  during  retinal  degeneration  (Zhao  
et  al.,  2015).  Thus  inflammatory  neuronal  loss  during  a  variety  of  brain  pathologies  may  involve  
microglial  phagocytosis  of  stressed-­but-­viable  neurons.  
We  have  identified  in  this  work  a  variety  of  targets  and/or  agents  that  prevent  Aβ-­induced  
neuronal  loss,  including:  TLR2  and  TLR4  (blocked  by  antibodies),  classical  PKCs  (blocked  by  Gö6976  
and  Gö6983),  PHOX  (blocked  by  AEBSF  and  apocynin),  superoxide  (removed  by  SOD),  MFG-­E8  
(genetic  knockout)  and  VNR  (blocked  by  cRGDfV)  (Fig.  9).  Thus  it  may  be  worth  testing  whether  
blocking  these  targets  is  neuroprotective  in  models  of  Alzheimer’s  disease  of  other  neuropathologies  
with  inflammatory  neuronal  loss.    Gö6976  has  previously  been  found  to  be  neuroprotective  in  an  
animal  model  of  inflammatory  neuronal  loss  (Dvoriantchikova  et  al.,  2014),  and  thus  might  have  
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potential  as  a  treatment  at  least  for  acute  pathologies.  Apocynin  is  neuroprotective  in  a  variety  of  
animal  models  of  brain  pathology,  but  it  is  not  known  whether  it  prevents  inflammatory  neuronal  loss  
in  Alzheimer’s  disease  (t  Hart  et  al.).  
  
5.  Conclusion  
   We  have  found  that  microglial  activation  by  Aβ  and  PMA  causes  neuronal  cell  death  by  
phagocytosis  (phagoptosis)  via  PKC  and  PHOX  activation.  A  possible  mechanism,  compatible  with  
our  data,  by  which  Aβ  and  PMA  induce  this  neuronal  loss  is  as  follows  (see  Fig.  9).  Aβ,  as  well  as  
bacterial  wall  components  such  as  LPS,  stimulate  microglia  by  binding  to  TLR2  and  TLR4,  which  
activate  classical  PKCs.  PKCs  can  also  be  activated  directly  either  by  PMA  or  by  diacylglycerol  (DAG)  
released  by  phospholipase  C  (PLC)  after  stimulation  with  fMLP.  PKCs  phosphorylate  p47phox  and  
other  subunits  of  NADPH  oxidase,  causing  assembly  and  activation  of  the  oxidase.  Superoxide  from  
NADPH  oxidase  reacts  with  NO,  produced  by  iNOS  induced  by  TLR2/4  activation,  to  form  
peroxynitrite  that  triggers  phosphatidylserine  exposure  on  neurons.  The  phosphatidylserine  on  the  
external  surface  of  neurons  is  bound  by  opsonin  MFG-­E8,  released  by  activated  glia,  and  the  bound  
MFG-­E8  is  in  turn  recognized  by  the  microglial  vitronectin  receptor  (VNR),  leading  to  the  engulfment  
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Figures  
  
Figure  1.  Aβ  induce  neuronal  loss  that  is  blocked  by  PKC  inhibitors  Gö6976  or  
Gö6983.  Mixed  neuronal-­glial  cultures  from  rat  cerebellum  were  untreated  (Control)  or  
treated  with  Aβ  (250  nM)  with  and  without  PKC  inhibitors  A:  Gö6976  (0.1  or  1  µM)  or  B:  
Gö6983  (0.1  or  1  µM),  and  after  3  days  the  density  of  neurons  that  were  necrotic  (staining  
with  propidium  iodide),  apoptotic  (chromatin  condensed,  but  not  necrotic)  or  alive  (neither  
apoptotic  nor  necrotic)  was  determined.  Data  are  presented  as  means  ±  s.e.m.  for  ≥  3  
independent  experiments;;  **/***  p  <  0.01/0.001  versus  untreated  Control,  ##/###  p  <  
0.01/0.001  versus  Aβ  alone.  
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Figure  2.  PMA  induces  neuronal  loss  mediated  by  microglia  and  blocked  by  PKC  
inhibitors.  Rat  neuronal-­glial  cultures  were  untreated  (Control)  or  treated  for  three  days  with  
PMA  (30  nM).  A:  Cell  nuclei  were  labelled  with  Hoechst  33342,  necrotic  cells  with  propidium  
iodide,  microglia  cells  with  isolectin  B4;;  scale  bars,  25  μm;;  in  phase  contrast  images,  
microglia  are  indicated  with  white  arrowheads.  B:  Cultures  were  treated  with  or  without  L-­
leucine-­methyl  ester  (LME)  to  eliminate  microglia.  C:  Cultures  were  treated  with  or  without  
PKC  inhibitor  Gö6976  (0.1-­1  μM).  D:  Cultures  were  treated  with  or  without  PKC  inhibitor  
Gö6983  (0.1-­1  μM).  Data  are  presented  as  means  ±  s.e.m.  for  ≥  3  independent  experiments;;  
**  p  <0.01  versus  untreated  Control,  #/##  p  <  0.05/0.01  versus  PMA  alone.  
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Figure  3.  PMA-­induced  neuronal  loss  is  unchanged  in  Bax-­/-­  cultures,  but  is  prevented  
by  genetic  deletion  of  MFG-­E8.  Neuronal-­glial  cultures  from  wild-­type,  Bax  knockout,  or  
Mfge8  knockout  mice  were  untreated  (Control)  or  treated  with  PMA  (30  nM),  and  after  3  
days  the  density  of  necrotic,  apoptotic  and  alive  neurons  was  determined.  Data  are  
presented  as  means  ±  s.e.m.  for  ≥  3  independent  experiments;;  *  p  <  0.05  versus  Control.  
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Figure  4.  PMA  increases  PKC/PHOX-­dependent  microglial  phagocytosis,  and  PMA-­
induced  neuronal  loss  is  prevented  by  blocking  the  phagocytic  vitronectin  receptor  
with  cRGDfV.  A:  Isolated  rat  microglia  were  untreated  (Control)  or  stimulated  with  PMA  
(30  nM)  for  24  hours  and  then  treated  with  or  without  Gö6976  (1  µM)  or  Gö6983  (1  µM)  for  
30  minutes.  After  adding  fluorescent,  negatively-­charged,  1  µm  beads  for  1  hour  the  number  
of  beads  within  the  microglia  was  determined.  B:  Rat  neuronal-­glial  cultures  were  untreated  
(Control)  or  treated  with  PMA  (30  nM),  PMA  +  cRGDfV  (50  µM),  cRGDfV  (50  µM)  or  PMA  +  
cRADfV  (50  µM),  and  after  3  days  the  density  of  necrotic,  apoptotic  and  alive  neurons  was  
determined.  Data  are  presented  as  means  ±  s.e.m.  for  ≥  3  independent  experiments;;  */**/***  
p  <  0.05/0.01/0.001  versus  HBSS  Control  (A)  or  unteated  Control  (B),  ###  p  <  0.001  versus  
PMA  alone  Control  (A)  or  PMA  alone  (B).  
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Figure  5.  Aβ  and  PMA  induce  microglial  oxidant  production,  and  superoxide  
dismutase  prevents  Aβ-­induced  neuronal  loss.  A  &  B:  Microglia  were  untreated  (Control,  
Ai),  treated  with  Aβ  (250  nM,  Aii),  or  PMA  (30  nM,  Aiii)  for  three  days,  and  then  ROS-­
producing  cells  were  identified  by  NBT  assay,  cells  were  imaged  (A)  and  NBT+  cells  counted  
(B).  C:  PMA  (30  nM)  acutely  increased  hydrogen  peroxide  production  by  isolated  rat  
microglia,  as  measured  with  Amplex  Red,  and  this  was  inhibited  by  co-­treatment  with  
Gö6976  (1  μM)  or  Gö6983  (1  μM).  D:  Neuronal-­glial  cultures  from  rats  were  untreated  
(Control)  or  treated  with  Aβ  (250  nM)  with  or  without  superoxide  dismutase  (SOD,  100  U/ml),  
and  after  3  days  neuronal  densities  were  determined.  Data  are  presented  as  means  ±  s.e.m.  
for  ≥  3  independent  experiments;;  */***  p  <0.05/  0.001  versus  untreated  Control,  ##/###  p  <  
0.01/0.001  versus  PMA  alone  (C)  or  Aβ  alone  (D).  
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Figure  6.  PHOX  inhibitors,  AEBSF  and  apocynin,  prevent  PMA-­  or  Aβ-­induced  
neuronal  loss.  Neuronal-­glial  cultures  from  rats  were  untreated  (Control)  or  treated  with  
PMA  (30  nM,  A  and  B)  or  Aβ  (250  nM,  C  and  D)  with  or  without  AEBSF  (20  µM,  A  and  C)  or  
apocynin  (100  µM,  B  and  D),  and  after  3  days  neuronal  densities  were  determined.  Data  are  
presented  as  means  ±  s.e.m.  for  ≥  3  independent  experiments;;  **/***  p  <  0.01/0.001  versus  
unteated  Control,  ##/###  p  <  0.01/0.001  versus  PMA  alone  (A,  B)  or  Aβ  alone  (C,  D).  













Figure  7.  Aβ-­induced  neuronal  loss  is  prevented  by  blocking  Toll-­like  receptors-­2  and  
-­4.  Neuronal-­glial  cultures  from  rats  were  either  untreated  or  pre-­treated  for  30  minutes  with  
A:  anti-­Toll-­like  receptor-­2  antibody  (α-­TLR2,  10  μg/ml)  or  control  immunoglobulin  (IgG1,  
10  μg/ml);;  B:  anti-­Toll-­like  receptor-­4  antibody  (α-­TLR4,  10  μg/ml)  or  control  immunoglobulin  
IgG2a  (IgG2a,  10  μg/ml);;  C:  both  α-­TLR2  and  α-­TLR4  or  IgGs  together  (10  μg/ml  each).  
Then  cultures  were  either  untreated  (Control)  or  treated  with  Aβ  (250  nM)  for  three  days,  
whereafter  neuronal  densities  were  determined.  Data  are  presented  as  means  ±  s.e.m.  for  ≥  
3  independent  experiments;;  */**  p  <  0.05/0.01  versus  untreated  Control,  #  p  <  0.05  versus  
Aβ  alone.  
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Figure  8.  fMLP  induces  neuronal  loss  mediated  by  microglia.  A:  Neuronal-­glial  cultures  
from  rats  were  untreated  (Control)  or  treated  with  fMLP  (10-­100  µM),  and  after  3  days  
neuronal  densities  were  determined.  B:  Cultures  were  pre-­treated  with  LME  to  remove  
microglia  and  then  treated  with  or  without  fMLP  (10  µM)  for  three  days.  Data  are  presented  
as  means  ±  s.e.m.  for  ≥  3  independent  experiments;;  **  p  <  0.01  versus  untreated  Control,  ##  
p  <  0.01  versus  fMLP  alone.  
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Fig  9.  Suggested  mechanism  by  which  Aβ  and  PMA  induce  neuronal  loss  by  
successively  activating  microglial  TLR2/4,  PKC,  NADPH  oxidase,  inducing  neuronal  
phosphatidylserine  (PS)  exposure  and  triggering  microglial  phagocytosis  of  these  neurons  
via  MFG-­E8  and  the  vitronectin  receptor  (VNR).  Activation  of  TLR2/4  also  causes  iNOS  
expression,  producing  NO  that  reacts  with  superoxide  from  NADPH  oxidase  to  form  
peroxynitrite  that  induces  PS  exposure.  fMLP  can  also  activate  PKCs  via  phospholipase  C  
(PLC)  and  its  product  diacylglycerol  (DAG).  Agents  blocking  neuronal  loss,  and  where  they  
act,  are  also  indicated.  
  
